Retireful LLC Buys Shares of 5,459 Edwards Lifesciences Co. (NYSE:EW)

Retireful LLC bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,459 shares of the medical research company's stock, valued at approximately $387,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Farmers & Merchants Investments Inc. grew its stake in shares of Edwards Lifesciences by 21.1% during the fourth quarter. Farmers & Merchants Investments Inc. now owns 134,341 shares of the medical research company's stock worth $9,945,000 after buying an additional 23,409 shares during the last quarter. Lockheed Martin Investment Management Co. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $4,499,000. Alyeska Investment Group L.P. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $49,038,000. Equitable Trust Co. grew its stake in shares of Edwards Lifesciences by 10.9% during the fourth quarter. Equitable Trust Co. now owns 73,042 shares of the medical research company's stock worth $5,407,000 after buying an additional 7,154 shares during the last quarter. Finally, Simplify Asset Management Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $5,979,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 0.2%

EW traded down $0.15 during midday trading on Thursday, hitting $77.70. The company had a trading volume of 2,257,761 shares, compared to its average volume of 5,204,147. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $45.58 billion, a price-to-earnings ratio of 11.15, a PEG ratio of 4.82 and a beta of 1.12. The stock's 50 day moving average price is $73.76 and its 200 day moving average price is $72.64.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.66 earnings per share. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the topic of a number of recent research reports. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday, May 13th. Evercore ISI cut their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Truist Financial cut their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Wolfe Research lowered shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Finally, Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of "Hold" and a consensus price target of $80.20.

Insider Transactions at Edwards Lifesciences

In related news, CEO Bernard J. Zovighian sold 6,164 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the transaction, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. The trade was a 9.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $77.40, for a total transaction of $198,918.00. Following the transaction, the vice president now owns 50,356 shares in the company, valued at approximately $3,897,554.40. This trade represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,012 shares of company stock valued at $4,224,717 over the last three months. Corporate insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.